Benoit Callendret
Overview
Explore the profile of Benoit Callendret including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Fits L, de Jong R, Dijkman K, Heemskerk-van der Meer M, Tettero L, Bonsing J, et al.
NPJ Vaccines
. 2024 Nov;
9(1):235.
PMID: 39587114
Vaccination with Ad26.RSV.preF, an Adenoviral serotype 26 vector encoding RSV F protein stabilized in its prefusion conformation, has previously shown to be immunogenic and protective in RSV seropositive adults and...
2.
Jastorff A, Gymnopoulou E, Salas J, Merrall E, Buntinx E, Martin C, et al.
Vaccine
. 2024 Nov;
43(Pt 1):126514.
PMID: 39536455
Background: Respiratory syncytial virus (RSV) causes a significant disease burden in adults with chronic comorbidities. Rates of severe RSV disease and death are as high, or higher in younger adults...
3.
van Heesbeen R, Bastian A, Omoruyi E, Rosen J, Comeaux C, Callendret B, et al.
Vaccine
. 2024 Sep;
42(26):126273.
PMID: 39276619
Background: Respiratory syncytial virus (RSV) can cause severe illness in older adults. A combination vaccine containing Ad26.RSV.preF and purified recombinant RSV preF protein has previously demonstrated efficacy and tolerability in...
4.
Langley J, Nolan T, Ramet M, Richmond P, Rosario Filho N, Haazen W, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae453.
PMID: 39220658
Background: Respiratory syncytial virus (RSV) causes serious illness in children. The Ad26.RSV.preF vaccine candidate was immunogenic with acceptable safety in a phase 1/2a study of RSV-seropositive children. Here, we assessed...
5.
Jastorff A, Bastian A, Ligtenberg N, Klyashtornyy V, Callendret B, Heijnen E
Hum Vaccin Immunother
. 2024 Aug;
20(1):2383504.
PMID: 39118413
The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)-related lower respiratory tract disease in a phase 2b study. This study compared the...
6.
Eto T, Okubo Y, Momose A, Tamura H, Zheng R, Callendret B, et al.
Influenza Other Respir Viruses
. 2024 Jun;
18(6):e13336.
PMID: 38880785
Background: Respiratory syncytial virus (RSV) is increasingly recognized as a significant cause of lower respiratory tract disease (LRTD) in older adults. The Ad26.RSV.preF/RSV preF protein vaccine demonstrated protective efficacy against...
7.
Falsey A, Hosman T, Bastian A, Vandenberghe S, Chan E, Douoguih M, et al.
Lancet Infect Dis
. 2024 May;
24(9):1015-1024.
PMID: 38801826
Background: Ad26.RSV.preF-RSV preF protein showed 80·0% vaccine efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in older adults during one RSV season. No RSV vaccines have shown...
8.
Hosman T, van Heesbeen R, Bastian A, Hu W, Comeaux C, Ligtenberg N, et al.
Hum Vaccin Immunother
. 2024 May;
20(1):2344970.
PMID: 38783590
This study assessed three Ad26.RSV.preF/RSV preF protein combinations, combining different Ad26.RSV.preF doses and naturally aged preF protein, representing the expected critical vaccine quality attributes close to release, around intermediate shelf-life...
9.
Widagdo W, Bastian A, Jastorff A, Scheys I, De Paepe E, Comeaux C, et al.
J Infect Dis
. 2023 Dec;
230(2):e374-e383.
PMID: 38134393
Background: Since influenza and respiratory syncytial virus (RSV) carry significant burden in older adults with overlapping seasonality, vaccines for both pathogens would ideally be coadministered in this population. Here we...
10.
Bartsch Y, Cizmeci D, Yuan D, Mehta N, Tolboom J, De Paepe E, et al.
J Virol
. 2023 Oct;
97(11):e0077123.
PMID: 37902399
Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness...